Feedback
Settings

Settings

Goto Application

4,670 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NIDVTARKFBZMOT-PEBGCTIMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 467
1.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
2.WO/2025/245111IMMUNORECEPTOR TARGETING PROTEINS AND RELATED METHODS
WO - 27.11.2025
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No PCT/US2025/030194 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunoreceptor targeting proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor targeting proteins and compositions. The immunoreceptor targeting proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., binding to (e.g., thereby targeting) cells expressing CD30L, inhibiting binding or reducing (e.g., preventing) of one or more TNSRSF member to one or more TNFLSF member (e.g., binding of CD30L to CD30).
3.WO/2025/244008MEASUREMENT METHOD, PROGRAM, AND HIGH-SPEED LIQUID CHROMATOGRAPH TANDEM MASS SPECTROMETER
WO - 27.11.2025
Int.Class G01N 27/62
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
62by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
 Appl.No PCT/JP2025/018148 Applicant SHIMADZU CORPORATION Inventor KUNISAWA, Akihiro
A method for measuring a creatinine correction value of a nucleoside according to the present disclosure includes a step (S10) for temporally separating a component, a step (S12) for acquiring a chromatogram of an ion derived from each component, a step (S14) for acquiring a nucleoside measurement value on the basis of a chromatogram of an ion of the nucleoside, a step (S16) for acquiring a creatinine measurement value on the basis of a chromatogram of a product ion other than the product ion having the highest ionic strength of creatinine, and a step (S18) for calculating a creatinine correction value of the nucleoside.
4.WO/2025/245361T CELL VACCINE
WO - 27.11.2025
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
 Appl.No PCT/US2025/030609 Applicant THE SCRIPPS RESEARCH INSTITUTE Inventor JARDINE, Joseph
The present invention relates to antigen presentation to CD8+ T cells. Systems and methods are provided for efficient presentation of diverse peptide antigens and induction of stimulatory and regulatory CD8+ T cell responses.
5.WO/2025/240659ACTIVATABLE CONSTRUCTS, COMPOSITIONS AND METHODS
WO - 20.11.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/US2025/029426 Applicant CYTOMX THERAPEUTICS, INC. Inventor FOX, Ellaine Anne Mariano
Activatable constructs and methods of making and treating using the same, comprising a first antigen binding domain (AB1) having specific binding affinity for a first antigen, wherein the AB1 comprises a heavy chain variable domain 1 (HVD1) and a light chain variable domain 1 (LVD1), wherein the HVD1 is covalently coupled directly or indirectly to a first masking moiety (MM1) via a first cleavable moiety (CM1), wherein the LVD1 is covalently coupled directly or indirectly to a second masking moiety (MM2) via a second cleavable moiety (CM2), a second antigen binding domain (AB2) having specific binding affinity for a second antigen, wherein the AB2 comprises a heavy chain variable domain 2 (HVD2) and a light chain variable domain 2 (LVD2), a first dimerization domain (DD1) and a second dimerization domain (DD2).
6.20250353881IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS
US - 20.11.2025
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No 19208911 Applicant Flagship Pioneering Innovations VII, LLC Inventor Hozefa Saifuddin BANDUKWALA

Provided herein are immunoreceptor inhibitory proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor inhibitory proteins and compositions. The immunoreceptor inhibitory proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., inhibiting binding of one or more TNFRSF member to one or more TNFLSF member (e.g., binding of TNFα to TNFR1 and/or TNFR2; and/or binding of LTα to TNFR1 and/or TNFR2).

7.20250352583Treatment of osteoarthritis and/or rheumatoid arthritis with pro-chondrogenic and/or chondrocyte protective factors
US - 20.11.2025
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
 Appl.No 19272688 Applicant SmartCella Solutions AB Inventor Ran YANG

The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and/or chondrocyte protective factor. The pro-chondrogenic and/or chondrocyte protective factor can be WNT3a.

8.WO/2025/237620A COMPUTATIONAL METHOD FOR SMALL RNA BIOMARKER MODIFICATION CLASSIFICATION
WO - 20.11.2025
Int.Class G16B 20/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
20Allele or variant detection, e.g. single nucleotide polymorphism detection
 Appl.No PCT/EP2025/060457 Applicant HUMMINGBIRD DIAGNOSTICS GMBH Inventor RAJAKUMAR, Timothy
The present invention relates to a method classifying target RNA modifications in a neural network system, to a method for training a neural network system that is configured to classify target RNA modifications, to a neural network system, to a computer system adapted to classify target RNA modifications, to a computer program and to a non-transitory readable medium.
9.WO/2025/240680IMMUNORECEPTOR INHIBITORY PROTEINS AND RELATED METHODS
WO - 20.11.2025
Int.Class C07K 14/065
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
065Poxviridae, e.g. avipoxvirus
 Appl.No PCT/US2025/029465 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunoreceptor inhibitory proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor inhibitory proteins and compositions. The immunoreceptor inhibitory proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., inhibiting binding of one or more TNFRSF member to one or more TNFLSF member (e.g., binding of TNFα to TNFR1 and/or TNFR2; and/or binding of LTα to TNFR1 and/or TNFR2).
10.WO/2025/240369METHODS OF DELIVERING NAKED POLYRIBONUCLEOTIDES
WO - 20.11.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2025/028984 Applicant HELIX NANOTECHNOLOGIES INC Inventor DHAR, Nikhil
The present disclosure provides methods of delivering naked polyribonucleotides. The present disclosure also provides polyribonucleotides that can be useful in such methods and kits comprising the same.
# -